This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Video Lectures
ASCO GU 2024
ASCO GU 2024 VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
Real-World Use of Nadofaragene Firadenovec - Siamak Daneshmand
Details
Sam Chang and Siamak (Sia) Daneshmand discuss the ABLE-41 trial, focusing on the real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial's design and objectives, they emphasize its significance in capturing diverse patient experiences and outcomes outside the confines of traditional clinical trials. With nadofaragene firadenovec's unique once-quarterly dosing schedule...
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
Details
Zach Klaassen and Daniel George discuss the highlights from ASCO GU 2024 including the BRCAAway trial, a study focusing on the combination of PARP inhibitors and novel hormonal agents for treating metastatic castration-resistant prostate cancer. Dr. George explains the trial's innovative design, which explored the efficacy of abiraterone and olaparib, both separately and in combination, in patient...
Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor
Details
Evan Yu and Oliver Sartor discuss the VISION trial's exploration of predictive and prognostic markers in the treatment of prostate cancer with Lutetium-PSMA-617. Sartor clarifies the distinction between predictive and prognostic markers, emphasizing the trial's focus on baseline markers and their association with treatment outcomes. The conversation highlights the importance of PSMA PET scans in p...
Start
Prev
1
2
3
4
5
Next
End
The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer - Nima Sharifi
April 25, 2024
Details
The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore
April 22, 2024
Details
NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer - Rana McKay
March 26, 2024
Details
The STEEL Trial: Evaluating Enzalutamide Plus ADT with Salvage RT for High-Risk Recurrent Prostate Cancer - Edwin Posadas
March 14, 2024
Details
Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston
March 13, 2024
Details
Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce
March 5, 2024
Details
CheckMate-67T: Subcutaneous Nivolumab Shows Comparable Results to IV, Reduces Treatment Burden in RCC - Saby George
March 5, 2024
Details
CheckMate-214 at 8 Years: Nivolumab + Ipilimumab Shows Durable Survival Benefit in Advanced RCC - Nizar Tannir
March 5, 2024
Details
Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore
March 5, 2024
Details
ARAMON Trial: Darolutamide Monotherapy and Testosterone Levels in Biochemically Recurrent Prostate Cancer - Andrew Laccetti
March 5, 2024
Details
Intravesical Erdafitinib (TAR-210) Demonstrates High Response Rates in NMIBC With Reduced Toxicity - Roger Li
March 4, 2024
Details
EV-302: Enfortumab Vedotin + Pembrolizumab Outperforms Chemo in Untreated Advanced Urothelial Cancer - Michiel Simon Van der Heijden
March 4, 2024
Details
Genetic Overlap Discovered Between Cancerous and Non-Cancerous Bladder Tissue in Small Study - Roger Li
March 4, 2024
Details
ANTICIPATE II Trial: APL-1202 and Tislelizumab for Neoadjuvant Bladder Cancer Treatment - Matthew Galsky
March 4, 2024
Details
Comprehensive Genetic Profiling May Optimize Targeted Therapy Selection for FGFR3-Mutated Urothelial Carcinoma Patients - Michael Basin
March 4, 2024
Details
The Economic Impact of Cystectomy vs Trimodal Bladder Therapy - Stephen Williams
March 1, 2024
Details
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans
March 1, 2024
Details
Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings - Andrea Apolo
March 1, 2024
Details
Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer - Amanda Nizam
March 1, 2024
Details
The Role of Nephrectomy with Immunotherapy in Metastatic Renal Cell Carcinoma - Dimitrios Makrakis
February 29, 2024
Details
Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer - María Bourlon
February 29, 2024
Details
Update on Biomarkers in Renal Cell Carcinoma - David Braun
February 29, 2024
Details
LIBERTAS Trial Tests Less Treatment, Better Quality of Life in Responding mHSPC Patients - Arun Azad
February 29, 2024
Details
The De-Escalate Trial: Intermittently Stopping Prostate Cancer Treatments to Improve Quality of Life - Guillaume Grisay
February 28, 2024
Details
Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore
February 28, 2024
Details
BCG Shortage: What’s on the Horizon to Replace? - Joshua Meeks
February 28, 2024
Details
Combination Maintenance Therapy for Advanced Bladder Cancer Explored in MAIN-CAV Study - Shilpa Gupta
February 28, 2024
Details
Analyzing Real-World Impact of Race on ADT Mortality in Prostate Cancer - Judd Moul
February 27, 2024
Details
High-Risk Prostate Cancer: 80Gy + ADT Extends Survival Without Added Toxicity - Christophe Hennequin
February 27, 2024
Details
PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik
February 27, 2024
Details
BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer - Maha Hussain
February 22, 2024
Details
Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell
February 22, 2024
Details
Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them? - Chana Weinstock
February 22, 2024
Details
KEYNOTE-564 Shows Overall Survival Benefit in Kidney Cancer with Pembrolizumab - Toni Choueiri
February 21, 2024
Details
CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal
February 21, 2024
Details
Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials - Cheryl Lee
February 21, 2024
Details
Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt
February 20, 2024
Details
Prostate Cancer Foundation's Guidelines for Black Men in the US - Isla Garraway
February 20, 2024
Details
Predicting Recurrence and Monitoring Response in BCG-Unresponsive NMIBC with Urinary Minimal Residual Disease Detection - Vikram Narayan
February 20, 2024
Details
The Efficacy and Resistance-Breaking Potential of EPI-7386 Masofaniten in Castration-Resistant Prostate Cancer - Andrew Laccetti
February 14, 2024
Details
Real-World Use of Nadofaragene Firadenovec - Siamak Daneshmand
February 7, 2024
Details
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
February 6, 2024
Details
Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor
February 2, 2024
Details
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
